LYN-1604 is primarily investigated for its potential therapeutic applications in cancer treatment. It functions as an inhibitor of ULK1, a key protein involved in autophagy, a cellular process that cancer cells often exploit for survival under stress conditions. By targeting ULK1, LYN-1604 disrupts autophagy, potentially making cancer cells more susceptible to other treatments like chemotherapy or radiation. Research is ongoing to explore its efficacy in various cancer types, particularly in combination therapies, to enhance overall treatment outcomes. Additionally, its role in modulating autophagy pathways may offer insights into other diseases where autophagy plays a critical role, such as neurodegenerative disorders.